Treatments for Uremic Pruritus Underway

Restricted access

Cara Therapeutics (Stamford, CT) released positive data about its uremic pruritus product, intravenous CR845, which targets peripheral kappa opioid receptors.

Cara noted that Part A of the Phase 2/3 trial achieved reduced itching and improved quality of life, the trial’s primary and secondary endpoints. The company intends to meet with the US Food and Drug Administration to finalize clinical study design for Part B of the trial as well as begin patient enrollment later in 2017, noted Cara Therapeutics President and Chief Executive Officer Derek Chalmers, PhD. Part B will include up to 240 participants and involve CR845 treatments just